Nuveen California Select Tax-Free Income Portfolio Key Executives
This section highlights Nuveen California Select Tax-Free Income Portfolio's key executives, including their titles and compensation details.
Find Contacts at Nuveen California Select Tax-Free Income Portfolio
(Showing 0 of )
Nuveen California Select Tax-Free Income Portfolio Earnings
This section highlights Nuveen California Select Tax-Free Income Portfolio's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
Time:
Est. EPS:
$-
Status:
Unconfirmed
Last Earnings Results
Date:
November 08, 2024
EPS:
$0.20
Est. EPS:
$-
Revenue:
$1.86M
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Nuveen California Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of California. The fund invests in the securities of companies that operate across diversified sectors. It primarily invests in municipal bonds. The fund employs fundamental analysis to create its portfolio. It benchmarks the performance of its portfolio against Barclays Capital California Municipal Bond Index and S&P California Municipal Bond Index. Nuveen California Select Tax-Free Income Portfolio was formed on June 19, 1992 and is domiciled in the United States.
Financial Services
Asset Management - Income
$12.59
Stock Price
$80.10M
Market Cap
-
Employees
Chicago, IL
Location
Financial Statements
Access annual & quarterly financial statements for Nuveen California Select Tax-Free Income Portfolio, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | February 29, 2024 | February 28, 2023 | February 28, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $5.19M | $-5.90M | $3.50M | $5.95M | $4.80M |
| Cost of Revenue | $1.49M | $267.74K | $- | $2.32M | $1.07M |
| Gross Profit | $3.70M | $-6.16M | $3.50M | $3.62M | $3.73M |
| Gross Profit Ratio | 71.25% | 104.54% | 100.00% | 60.92% | 77.65% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $87.04K | $92.50K | $350.37K | $92.50K | $97.51K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $87.04K | $92.50K | $350.37K | $92.50K | $97.51K |
| Other Expenses | $- | $-7.57M | $- | $2.27K | $2.41K |
| Operating Expenses | $89.00K | $94.82K | $350.37K | $94.77K | $99.92K |
| Cost and Expenses | $89.00K | $94.82K | $350.37K | $2.23M | $973.61K |
| Interest Income | $3.70M | $3.55M | $- | $- | $- |
| Interest Expense | $1.80K | $44 | $- | $- | $- |
| Depreciation and Amortization | $- | $-3.23M | $-3.15M | $-3.27M | $-3.38M |
| EBITDA | $5.10M | $-5.99M | $- | $2.58M | $1.33M |
| EBITDA Ratio | 98.32% | 101.61% | 0.00% | 43.41% | 27.66% |
| Operating Income | $5.10M | $-5.99M | $3.15M | $3.27M | $3.38M |
| Operating Income Ratio | 98.28% | 101.61% | 89.99% | 54.99% | 70.26% |
| Total Other Income Expenses Net | $- | $-5.72M | $-4.54M | $- | $- |
| Income Before Tax | $5.10M | $-5.99M | $-1.39M | $5.85M | $4.70M |
| Income Before Tax Ratio | 98.28% | 101.61% | -39.73% | 98.41% | 97.92% |
| Income Tax Expense | $- | $3.23M | $- | $2.58M | $1.33M |
| Net Income | $5.10M | $-5.99M | $-1.39M | $5.85M | $4.70M |
| Net Income Ratio | 98.28% | 101.61% | -39.73% | 98.41% | 97.92% |
| EPS | $0.80 | $-0.94 | $0.00 | $0.92 | $0.74 |
| EPS Diluted | $0.80 | $-0.94 | $0.00 | $0.92 | $0.74 |
| Weighted Average Shares Outstanding | 6.36M | 6.36M | - | 6.36M | 6.35M |
| Weighted Average Shares Outstanding Diluted | 6.36M | 6.36M | - | 6.36M | 6.35M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | August 31, 2024 | February 29, 2024 | August 29, 2023 | February 28, 2023 | August 31, 2022 | February 28, 2022 | September 30, 2021 | March 31, 2021 | September 30, 2020 | March 31, 2020 | September 30, 2019 | March 31, 2019 | September 30, 2018 | March 31, 2018 | September 30, 2017 | March 31, 2017 | September 30, 2016 | March 31, 2016 | September 30, 2015 | March 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86M | $1.85M | $1.85M | $1.82M | $1.73M | $1.73M | $1.77M | $1.79M | $1.84M | $1.84M | $1.90M | $1.53M | $1.84M | $1.94M | $2.01M | $2.03M | $2.12M | $2.17M | $2.21M | $2.25M |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $142.37K | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $1.86M | $1.85M | $1.85M | $1.82M | $1.73M | $1.73M | $1.77M | $1.79M | $1.84M | $1.84M | $1.90M | $1.38M | $1.84M | $1.94M | $2.01M | $2.03M | $2.12M | $2.17M | $2.21M | $2.25M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 90.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $179.31K | $155.05K | $-68.01K | $156.91K | $166.26K | $173.06K | $177.31K | $179.13K | $173.29K | $185.18K | $169.86K | $85.52K | $346.10K | $176.61K | $183.07K | $176.94K | $182.43K | $176.57K | $175.47K | $176.35K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $179.31K | $155.05K | $-68.01K | $156.91K | $166.26K | $173.06K | $177.31K | $179.13K | $173.29K | $185.18K | $169.86K | $85.52K | $346.10K | $176.61K | $183.07K | $176.94K | $182.43K | $176.57K | $175.47K | $176.35K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.62M | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $179.31K | $155.05K | $1.25M | $1.53M | $8.01M | $173.06K | $177.31K | $135.16K | $2.09M | $1.97M | $2.94M | $-2.62M | $1.45M | $1.73M | $1.98M | $5.00M | $1.07M | $2.50M | $1.67M | $1.37M |
| Cost and Expenses | $179.31K | $155.05K | $1.25M | $1.53M | $8.01M | $173.06K | $177.31K | $135.16K | $2.09M | $1.97M | $2.94M | $-2.47M | $1.45M | $1.73M | $1.98M | $5.00M | $1.07M | $2.50M | $1.67M | $1.37M |
| Interest Income | $- | $- | $3.70M | $1.06K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $3.36K | $-1.56K | $- | $1.10K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $-1.68M | $-1.69M | $4.50M | $-1.66M | $-1.57M | $-1.56M | $-1.59M | $-1.61M | $-1.66M | $-1.65M | $-1.73M | $-853.71K | $-1.50M | $-1.77M | $-1.82M | $-1.86M | $-1.94M | $-2.00M | $-2.03M | $-2.07M |
| EBITDA | $- | $4.11M | $986.64K | $-1.37M | $-7.84M | $- | $- | $314.30K | $2.27M | $-1.78M | $3.11M | $4.00M | $-721.73K | $-1.56M | $- | $-4.82M | $1.25M | $2.68M | $-1.49M | $1.55M |
| EBITDA Ratio | 0.00% | 222.60% | 53.39% | -75.57% | -452.89% | 0.00% | 0.00% | 17.59% | 123.48% | -97.03% | 164.07% | 262.00% | -39.19% | -80.13% | 0.00% | -237.14% | 59.06% | 123.35% | -67.69% | 68.97% |
| Operating Income | $1.68M | $1.69M | $598.93K | $1.66M | $1.57M | $1.56M | $1.59M | $1.61M | $1.66M | $1.65M | $1.73M | $4.00M | $1.50M | $1.77M | $1.82M | $1.86M | $1.94M | $2.00M | $2.03M | $2.07M |
| Operating Income Ratio | 90.36% | 91.61% | 32.41% | 91.37% | 90.40% | 90.02% | 89.97% | 89.97% | 90.56% | 89.91% | 91.04% | 262.00% | 81.21% | 90.91% | 90.88% | 91.30% | 91.41% | 91.87% | 92.04% | 92.16% |
| Total Other Income Expenses Net | $-404.72K | $6.53M | $-3.72M | $-1.37M | $-7.84M | $-4.19M | $-351.50K | $314.30K | $2.27M | $-1.78M | $3.11M | $- | $-1.11M | $-1.56M | $2.16M | $-7.79M | $4.45M | $7.36M | $-1.49M | $1.55M |
| Income Before Tax | $1.28M | $8.22M | $-3.12M | $287.46K | $-6.28M | $-2.63M | $1.24M | $1.92M | $3.93M | $-130.69K | $4.83M | $4.00M | $386.91K | $209.27K | $3.98M | $-2.97M | $3.20M | $4.68M | $537.13K | $3.62M |
| Income Before Tax Ratio | 68.59% | 445.01% | -169.10% | 15.80% | -362.49% | -151.65% | 70.08% | 107.56% | 214.05% | -7.12% | 255.10% | 262.00% | 21.01% | 10.78% | 198.51% | -145.84% | 150.47% | 215.23% | 24.35% | 161.13% |
| Income Tax Expense | $- | $- | $- | $-1.37M | $-7.85M | $- | $- | $314.30K | $2.27M | $-1.78M | $3.11M | $853.71K | $-1.11M | $-1.56M | $2.16M | $-4.82M | $1.25M | $2.68M | $-1.49M | $1.55M |
| Net Income | $1.28M | $4.11M | $986.52K | $287.46K | $-6.28M | $-2.63M | $1.24M | $1.92M | $3.93M | $-130.69K | $4.83M | $4.00M | $386.91K | $209.27K | $3.98M | $-2.97M | $3.20M | $4.68M | $537.13K | $3.62M |
| Net Income Ratio | 68.59% | 222.51% | 53.39% | 15.80% | -362.49% | -151.65% | 70.08% | 107.56% | 214.05% | -7.12% | 255.10% | 262.00% | 21.01% | 10.78% | 198.51% | -145.84% | 150.47% | 215.23% | 24.35% | 161.13% |
| EPS | $0.20 | $1.29 | $-0.49 | $0.05 | $-0.98 | $-0.19 | $0.19 | $0.30 | $0.62 | $-0.02 | $0.76 | $0.63 | $0.06 | $0.03 | $0.62 | $-0.48 | $0.50 | $0.74 | $0.09 | $0.58 |
| EPS Diluted | $0.20 | $1.29 | $-0.49 | $0.05 | $-0.98 | $-0.19 | $0.19 | $0.30 | $0.62 | $-0.02 | $0.76 | $0.63 | $0.06 | $0.03 | $0.62 | $-0.48 | $0.50 | $0.74 | $0.09 | $0.58 |
| Weighted Average Shares Outstanding | 6.36M | 6.36M | 6.36M | 12.72M | 12.72M | - | 6.36M | 12.71M | 12.71M | 12.70M | 12.70M | 6.35M | 6.35M | 6.35M | 6.33M | 6.29M | 6.28M | 6.28M | 6.28M | 6.28M |
| Weighted Average Shares Outstanding Diluted | 6.36M | 6.36M | 6.36M | 12.72M | 12.72M | - | 6.36M | 12.71M | 12.71M | 12.70M | 12.70M | 6.35M | 6.35M | 6.35M | 6.33M | 6.29M | 6.28M | 6.28M | 6.28M | 6.28M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | February 29, 2024 | February 28, 2023 | February 28, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $118.75K | $959.41K | $- | $1.09M | $- |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $118.75K | $959.41K | $- | $1.09M | $- |
| Net Receivables | $812.81K | $906.26K | $2.82M | $1.05M | $1.80M |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $- | $- | $-2.82M | $-2.14M | $- |
| Total Current Assets | $931.56K | $1.87M | $2.82M | $2.14M | $1.80M |
| Property Plant Equipment Net | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $88.22M | $85.69M | $94.48M | $99.37M | $97.18M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $-85.69M | $32.60K | $-99.37M | $-97.18M |
| Total Non-Current Assets | $88.22M | $85.69M | $94.51M | $99.37M | $97.18M |
| Other Assets | $194.86K | $30.57K | $- | $28.76K | $25.09K |
| Total Assets | $89.34M | $87.59M | $97.33M | $101.54M | $99.00M |
| Account Payables | $278.84K | $267.47K | $- | $829.61K | $266.35K |
| Short Term Debt | $- | $- | $621.88K | $- | $626.46K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $-626.46K |
| Other Current Liabilities | $-278.84K | $-267.47K | $357.19K | $-829.61K | $-892.81K |
| Total Current Liabilities | $297.11K | $267.47K | $979.06K | $943.57K | $991.95K |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $367.40K | $357.19K | $943.57K | $626.46K |
| Other Liabilities | $375.24K | $-367.40K | $-357.19K | $-943.57K | $-626.46K |
| Total Liabilities | $375.24K | $267.47K | $979.06K | $943.57K | $991.95K |
| Preferred Stock | $0 | $0 | $- | $100.60M | $98.01M |
| Common Stock | $63.62K | $63.62K | $63.61K | $63.56K | $63.52K |
| Retained Earnings | $355.14K | $-1.38M | $7.76M | $12.08M | $9.56M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $-0 | $-0 | $-0 |
| Other Total Stockholders Equity | $88.55M | $88.54M | $88.53M | $88.45M | $88.39M |
| Total Stockholders Equity | $88.97M | $87.22M | $96.35M | $100.60M | $98.01M |
| Total Equity | $88.97M | $87.22M | $96.35M | $100.60M | $98.01M |
| Total Liabilities and Stockholders Equity | $89.34M | $87.59M | $97.33M | $101.54M | $99.00M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $89.34M | $87.59M | $97.33M | $101.54M | $99.00M |
| Total Investments | $88.22M | $85.69M | $94.48M | $99.37M | $97.18M |
| Total Debt | $- | $- | $621.88K | $- | $626.46K |
| Net Debt | $-118.75K | $-959.41K | $621.88K | $-1.09M | $626.46K |
Balance Sheet Charts
| Breakdown | August 31, 2024 | February 29, 2024 | August 31, 2023 | February 28, 2023 | August 31, 2022 | September 30, 2021 | March 31, 2021 | September 30, 2020 | March 31, 2020 | September 30, 2019 | March 31, 2019 | September 30, 2018 | March 31, 2018 | September 30, 2017 | March 31, 2017 | September 30, 2016 | March 31, 2016 | September 30, 2015 | March 31, 2015 | September 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.29M | $118.75K | $706.78K | $959.41K | $1.12M | $216.34K | $1.09M | $144.28K | $- | $147.56K | $206.73K | $- | $2.79M | $- | $481.38K | $87.77K | $666.88K | $2.47M | $1.30M | $800.52K |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.39M | $1.89M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.29M | $118.75K | $706.78K | $959.41K | $1.12M | $216.34K | $1.09M | $144.28K | $- | $147.56K | $206.73K | $- | $2.79M | $- | $481.38K | $87.77K | $666.88K | $2.47M | $1.30M | $800.52K |
| Net Receivables | $957.38K | $812.81K | $1.64M | $906.26K | $944.78K | $3.08M | $1.05M | $1.30M | $1.80M | $1.16M | $1.27M | $1.45M | $4.19M | $1.24M | $2.20M | $1.09M | $1.02M | $960.50K | $982.92K | $1.02M |
| Inventory | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $2.70M | $3.36M | $- | $- | $- | $- | $- | $1 | $- | $- | $- |
| Other Current Assets | $- | $- | $- | $- | $0 | $-1 | $-2.14M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $0 | $0 | $- |
| Total Current Assets | $2.25M | $931.56K | $2.35M | $1.87M | $2.06M | $3.30M | $2.14M | $1.45M | $1.80M | $1.31M | $1.47M | $1.45M | $6.98M | $1.24M | $2.68M | $1.18M | $1.69M | $3.43M | $2.28M | $1.82M |
| Property Plant Equipment Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $86.42M | $88.22M | $84.46M | $85.69M | $86.78M | $97.48M | $99.37M | $99.37M | $97.18M | $98.79M | $95.42M | $94.27M | $88.66M | $96.45M | $91.98M | $98.95M | $97.18M | $93.93M | $98.97M | $95.16M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $188.06K | $- | $-84.46M | $-85.69M | $-86.78M | $-97.48M | $-99.37M | $-99.37M | $-97.18M | $-98.79M | $-95.42M | $-94.27M | $-88.66M | $-96.45M | $23.35K | $20.31K | $23.80K | $20.55K | $12.72K | $16.40K |
| Total Non-Current Assets | $86.61M | $88.22M | $84.46M | $85.69M | $86.78M | $97.48M | $99.37M | $99.37M | $97.18M | $98.79M | $95.42M | $94.27M | $88.66M | $96.45M | $92.01M | $98.97M | $97.20M | $93.95M | $98.98M | $95.18M |
| Other Assets | $- | $194.86K | $170.80K | $30.57K | $29.41K | $33.38K | $28.76K | $26.02K | $25.09K | $27.54K | $22.85K | $25.55K | $86.06K | $150.50K | $- | $- | $- | $- | $- | $- |
| Total Assets | $88.86M | $89.34M | $86.98M | $87.59M | $88.88M | $100.81M | $101.54M | $100.85M | $99.00M | $100.12M | $96.92M | $95.75M | $95.73M | $97.84M | $94.69M | $100.15M | $98.89M | $97.38M | $101.27M | $96.99M |
| Account Payables | $- | $278.84K | $265.82K | $267.47K | $245.74K | $351.50K | $829.61K | $457.58K | $266.35K | $266.61K | $249.87K | $269.09K | $268.98K | $292.29K | $- | $- | $- | $1.10M | $3.43M | $- |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.22M | $- | $400.24K | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $-360.11K | $- | $- | $-951.50K | $- | $-107.95K | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $352.97K | $-278.84K | $-265.82K | $-267.47K | $-245.74K | $-351.50K | $-829.61K | $-457.58K | $-266.35K | $-266.61K | $-249.87K | $-1.49M | $-268.98K | $-692.53K | $381.63K | $385.51K | $395.33K | $393.01K | $416.70K | $403.53K |
| Total Current Liabilities | $352.97K | $297.11K | $265.82K | $267.47K | $328.41K | $453.31K | $829.61K | $457.58K | $266.35K | $266.61K | $249.87K | $269.09K | $268.98K | $292.29K | $381.63K | $385.51K | $395.33K | $1.49M | $3.85M | $403.53K |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $421.88K | $367.40K | $328.41K | $453.31K | $943.57K | $542.23K | $626.46K | $345.92K | $344.22K | $1.22M | $- | $400.24K | $- | $- | $- | $- | $- | $- |
| Other Liabilities | $- | $375.24K | $-421.88K | $-367.40K | $-328.41K | $-453.31K | $-829.61K | $-457.58K | $99.15K | $-266.61K | $-249.87K | $85.16K | $368.11K | $108.14K | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $352.97K | $375.24K | $265.82K | $267.47K | $328.41K | $453.31K | $943.57K | $542.23K | $991.95K | $345.92K | $344.22K | $1.57M | $368.11K | $800.68K | $381.63K | $385.51K | $395.33K | $1.49M | $3.85M | $403.53K |
| Preferred Stock | $- | $0 | $- | $0 | $88.55M | $100.36M | $- | $- | $0 | $1 | $1 | $1 | $- | $- | $1 | $- | $1 | $1 | $- | $- |
| Common Stock | $63.62K | $63.62K | $63.62K | $63.62K | $63.61K | $63.59K | $63.56K | $63.53K | $63.52K | $63.50K | $63.50K | $63.50K | $63.50K | $63.26K | $62.87K | $62.85K | $62.81K | $62.79K | $62.78K | $62.74K |
| Retained Earnings | $-106.15K | $355.14K | $-2.06M | $-1.38M | $-47.58K | $11.79M | $12.08M | $11.83M | $9.56M | $11.36M | $8.15M | $5.58M | $-167.12K | $-140.54K | $6.68M | $12.16M | $10.95M | $8.38M | $9.93M | $9.15M |
| Accumulated Other Comprehensive Income Loss | $-0 | $- | $-0 | $-0 | $0 | $-0 | $-0 | $0 | $-0 | $0 | $0 | $0 | $0 | $-0 | $-0 | $-0 | $-0 | $0 | $-0 | $-0 |
| Other Total Stockholders Equity | $88.55M | $88.55M | $88.55M | $88.54M | $88.53M | $88.50M | $88.45M | $88.41M | $88.39M | $88.36M | $88.36M | $88.53M | $95.46M | $97.12M | $87.57M | $87.54M | $87.49M | $87.45M | $87.43M | $87.37M |
| Total Stockholders Equity | $88.51M | $88.97M | $86.56M | $87.22M | $88.55M | $100.36M | $100.60M | $100.30M | $98.01M | $99.78M | $96.57M | $94.17M | $95.36M | $97.04M | $94.31M | $99.76M | $98.49M | $95.89M | $97.42M | $96.59M |
| Total Equity | $88.51M | $88.97M | $86.56M | $87.22M | $88.55M | $100.36M | $100.60M | $100.30M | $98.01M | $99.78M | $96.57M | $94.17M | $95.36M | $97.04M | $94.31M | $99.76M | $98.49M | $95.89M | $97.42M | $96.59M |
| Total Liabilities and Stockholders Equity | $88.86M | $89.34M | $86.98M | $87.59M | $88.88M | $100.81M | $101.54M | $100.85M | $99.00M | $100.12M | $96.92M | $95.75M | $95.73M | $97.84M | $94.69M | $100.15M | $98.89M | $97.38M | $101.27M | $96.99M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $88.86M | $89.34M | $86.98M | $87.59M | $88.88M | $100.81M | $101.54M | $100.85M | $99.00M | $100.12M | $96.92M | $95.75M | $95.73M | $97.84M | $94.69M | $100.15M | $98.89M | $97.38M | $101.27M | $96.99M |
| Total Investments | $86.42M | $88.22M | $84.46M | $85.69M | $86.78M | $97.48M | $99.37M | $99.37M | $97.18M | $98.79M | $95.42M | $94.27M | $88.66M | $96.45M | $91.98M | $98.95M | $97.18M | $93.93M | $98.97M | $95.16M |
| Total Debt | $- | $- | $- | $- | $- | $- | $- | $- | $626.46K | $- | $- | $1.22M | $- | $400.24K | $- | $- | $- | $- | $- | $- |
| Net Debt | $-1.29M | $-118.75K | $-706.78K | $-959.41K | $-1.12M | $-216.34K | $-1.09M | $-144.28K | $626.46K | $-147.56K | $-206.73K | $1.22M | $-2.79M | $400.24K | $-481.38K | $-87.77K | $-666.88K | $-2.47M | $-1.30M | $-800.52K |
Annual Cash Flow
| Breakdown | February 29, 2024 | February 28, 2023 | February 28, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $5.10M | $-5.99M | $-1.39M | $5.85M | $4.70M |
| Depreciation and Amortization | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- |
| Change in Working Capital | $- | $- | $- | $- | $- |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- |
| Other Non Cash Items | $-5.10M | $5.99M | $1.39M | $-5.85M | $-4.70M |
| Net Cash Provided by Operating Activities | $- | $- | $- | $- | $- |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $- | $- | $- | $- | $- |
| Cash at End of Period | $- | $- | $1.09M | $- | $206.73K |
| Cash at Beginning of Period | $- | $- | $1.09M | $- | $206.73K |
| Operating Cash Flow | $- | $- | $- | $- | $- |
| Capital Expenditure | $- | $- | $- | $- | $- |
| Free Cash Flow | $- | $- | $- | $- | $- |
Cash Flow Charts
| Breakdown | August 31, 2024 | February 29, 2024 | August 29, 2023 | February 28, 2023 | August 28, 2022 | February 28, 2022 | August 28, 2021 | March 31, 2021 | September 30, 2020 | March 31, 2020 | September 30, 2019 | March 31, 2019 | September 30, 2018 | March 31, 2018 | September 30, 2017 | March 31, 2017 | September 30, 2016 | March 31, 2016 | September 30, 2015 | March 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.28M | $2.55M | $2.55M | $-3.00M | $-3.00M | $-695.38K | $-695.38K | $2.93M | $2.93M | $2.35M | $2.35M | $2.19M | $2.19M | $2.10M | $2.10M | $115.67K | $115.67K | $2.61M | $2.61M | $4.66M |
| Depreciation and Amortization | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non Cash Items | $-1.28M | $-2.55M | $-2.55M | $3.00M | $3.00M | $695.38K | $695.38K | $-2.93M | $-2.93M | $-2.35M | $-2.35M | $-2.19M | $-2.19M | $-2.10M | $-2.10M | $-115.67K | $-115.67K | $-2.61M | $-2.61M | $-4.66M |
| Net Cash Provided by Operating Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.58M | $-2.58M | $- | $- | $- | $- | $- | $- | $- |
| Cash at End of Period | $- | $- | $- | $- | $- | $1.09M | $1.09M | $- | $- | $206.73K | $206.73K | $206.73K | $206.73K | $- | $- | $- | $- | $- | $- | $- |
| Cash at Beginning of Period | $- | $- | $- | $- | $- | $1.09M | $1.09M | $- | $- | $206.73K | $206.73K | $2.79M | $2.79M | $- | $- | $- | $- | $- | $- | $- |
| Operating Cash Flow | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Nuveen California Select Tax-Free Income Portfolio Dividends
Explore Nuveen California Select Tax-Free Income Portfolio's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
0.00x
Nuveen California Select Tax-Free Income Portfolio Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.0455 | $0.0455 | April 15, 2025 | April 15, 2025 | May 01, 2025 | |
| $0.0455 | $0.0455 | March 14, 2025 | March 14, 2025 | April 01, 2025 | March 03, 2025 |
| $0.0455 | $0.0455 | February 14, 2025 | February 14, 2025 | March 03, 2025 | February 03, 2025 |
| $0.0455 | $0.0455 | January 15, 2025 | January 15, 2025 | February 03, 2025 | January 02, 2025 |
| $0.0455 | $0.0455 | December 13, 2024 | December 13, 2024 | December 31, 2024 | December 02, 2024 |
| $0.0455 | $0.0455 | November 15, 2024 | November 15, 2024 | December 02, 2024 | November 01, 2024 |
| $0.0455 | $0.0455 | October 15, 2024 | October 15, 2024 | November 01, 2024 | October 01, 2024 |
| $0.0455 | $0.0455 | September 13, 2024 | September 13, 2024 | October 01, 2024 | September 03, 2024 |
| $0.0455 | $0.0455 | August 15, 2024 | August 15, 2024 | September 03, 2024 | August 01, 2024 |
| $0.0455 | $0.0455 | July 15, 2024 | July 15, 2024 | August 01, 2024 | July 01, 2024 |
| $0.0455 | $0.0455 | June 14, 2024 | June 14, 2024 | July 01, 2024 | June 03, 2024 |
| $0.046 | $0.046 | May 14, 2024 | |||
| $0.0455 | $0.0455 | April 12, 2024 | April 15, 2024 | May 01, 2024 | April 01, 2024 |
| $0.0455 | $0.0455 | March 14, 2024 | March 15, 2024 | April 01, 2024 | March 01, 2024 |
| $0.0455 | $0.0455 | February 14, 2024 | February 15, 2024 | March 01, 2024 | February 01, 2024 |
| $0.0455 | $0.0455 | January 11, 2024 | January 12, 2024 | February 01, 2024 | January 02, 2024 |
| $0.0435 | $0.0435 | November 14, 2023 | November 15, 2023 | December 01, 2023 | October 23, 2023 |
| $0.0435 | $0.0435 | October 12, 2023 | October 13, 2023 | November 01, 2023 | October 02, 2023 |
| $0.0435 | $0.0435 | September 14, 2023 | September 15, 2023 | October 02, 2023 | September 01, 2023 |
| $0.0435 | $0.0435 | August 14, 2023 | August 15, 2023 | September 01, 2023 | August 01, 2023 |
Nuveen California Select Tax-Free Income Portfolio News
Read the latest news about Nuveen California Select Tax-Free Income Portfolio, including recent articles, headlines, and updates.
Sell Equities, Buy Municipal Debt At A 7.21% Discount With Nuveen California Select Tax-Free Income Portfolio
Municipal CEFs like Nuveen California Select Tax-Free Income Portfolio offer tax-free returns, low leverage, and are currently trading at a discount. NXC invests in high-quality municipal securities, with an average coupon of 3.68% and a distribution rate on NAV of 3.97%. The fund's market price is $13.17, NAV is $13.69, and it's trading at a 3.80% discount, presenting a potential profit opportunity.
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL Amyloidosis RMAT designation potentially streamlines the path to market approval by allowing frequent interactions with FDA and routes to FDA Accelerated Approval and Priority Review Enrollment in NEXICART-2 study accelerating; next update planned for H1 2025 LOS ANGELES,CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and select immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis. As of June 2024 public information, FDA approved less than half of RMAT applications submitted to the agency during the last eight years.
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an investigational CAR-T therapy, in patients relapsed/refractory (R/R) AL Amyloidosis. Achievement of this milestone is expected to accelerate enrollment across U.S. study sites beginning in January 2025.
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients LOS ANGELES, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, announced today the Journal of Clinical Oncology (JCO) published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The data reported on 16 enrolled patients in NEXICART-1 who had received a median 4 prior lines of therapy prior to treatment with NXC-201.
Nuveen Closed-End Funds Declare Distributions and Updates to Distribution Policies
NEW YORK--(BUSINESS WIRE)--Nuveen Closed-End Funds today announced that the Board of Trustees of the Funds has approved the regular monthly and quarterly distributions. In addition, the Board of Trustees has approved updated distribution polices described below under “Monthly & Quarterly Distributions” for The Nuveen Preferred & Income Opportunities Fund (NYSE: JPC), Nuveen Preferred and Income Term Fund (NYSE: JPI), Nuveen Variable Rate Preferred & Income Fund (NYSE: NPFD), Nuveen.
Similar Companies
C
Virtus Convertible & Income 2024 Target Term Fund
CBH
Price: $9.19
Market Cap: $167.75M
E
Eaton Vance National Municipal Opportunities Trust
EOT
Price: $15.76
Market Cap: $246.25M
M
BlackRock MuniHoldings New York Quality Fund, Inc.
MHN
Price: $9.79
Market Cap: $296.07M
Related Metrics
Explore detailed financial metrics and analysis for NXC.